Executive summary
FDA’s Center for Tobacco Products is adjusting its product review process to emphasize tobacco harm reduction, category-specific assessments, and more predictable timelines, while acknowledging staffing and backlog constraints.
FDA’s Center for Tobacco Products (CTP) is reworking its approach to reviewing tobacco products, including e-cigarettes and other ENDS, based on on-site reporting from New York and Washington. The changes aim to strengthen the link between PMTA decisions and tobacco harm reduction principles, introduce more category-specific review frameworks, and prioritize decision-relevant science in evaluations.
CTP is also working to establish more predictable review timelines and expand the use of supplemental PMTA (sPMTA) pathways for product modifications. These shifts reflect an effort to streamline authorization processes for existing products seeking updates, such as changes to e-liquid formulations or device components.
Regulatory signal: CTP’s increased reliance on sPMTA could reduce review burdens for minor product changes, potentially accelerating market access for compliant modifications.
Despite these procedural adjustments, CTP acknowledged significant operational constraints. The agency reported having only nine dedicated PMTA review teams, which contributes to persistent backlogs and limits its capacity to hire additional staff. These resource limitations continue to affect the speed and predictability of product authorizations across the ENDS market.
Market impact: Ongoing staffing constraints and backlogs may delay new product introductions and modifications, affecting innovation cycles for vape manufacturers operating under FDA oversight.
The revised review approach emphasizes aligning PMTA outcomes with public health goals related to harm reduction, particularly for products that may serve as alternatives to combustible tobacco. CTP’s focus on category-specific science aims to tailor evaluations to the distinct risk profiles of different product types, such as open tank systems, pod devices, and nicotine salts.
Expanded use of sPMTA is intended to provide a clearer, more efficient route for manufacturers to seek authorization for product changes that do not alter the product’s fundamental characteristics or intended use. This could benefit companies seeking to update flavors, adjust nicotine concentrations, or modify hardware while remaining within the scope of an existing PMTA.
However, the narrow review team structure and hiring limits suggest that procedural improvements may be constrained by systemic capacity issues. Operators should expect that while review criteria are becoming more transparent and predictable, overall throughput may remain limited by staffing availability.
The shifts in CTP’s review strategy reflect a broader effort to balance regulatory rigor with market functionality, particularly as the agency navigates ongoing litigation and political scrutiny over its ENDS authorization decisions. By clarifying expectations around harm reduction and sPMTA use, CTP aims to reduce uncertainty for applicants while maintaining scientific rigor in its evaluations.
For more daily vaping news, check out dawsenai.com
Original source: 2FIRSTS | Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
For more daily vaping news, check out dawsenai.com.
Written by
Comments
